Repaglinide versus glyburide: a one-year comparison trial.

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Type 2 diabetes mellitus (T2DM) management requires effective glycemic control.
• Oral antihyperglycemic agents play a crucial role in T2DM treatment.
• Comparing the efficacy and safety of different antidiabetic medications is essential for clinical practice.

Purpose of the Study:

• To demonstrate that repaglinide is at least equivalent to glyburide in patients with type 2 diabetes.
• To evaluate the long-term efficacy and safety profiles of repaglinide versus glyburide monotherapy.
• To assess the impact of these treatments on glycemic control, C-peptide, insulin, and lipid profiles.

Main Methods:

• A 1-year, prospective, multicenter, double-blind, randomized, parallel-group study.
• 576 patients with type 2 diabetes received either repaglinide or glyburide monotherapy.
• Dose adjustments were made to achieve target fasting plasma glucose (FPG) levels, with efficacy assessed via glycemic parameters and biochemical profiles.

Main Results:

• Repaglinide achieved glycemic control at least as effectively as glyburide, with potentially improved safety.
• Pharmacotherapy-naive patients on repaglinide showed significant reductions in glycosylated hemoglobin and FPG.
• Similar overall safety, lipid profiles, and body weight changes were observed, though repaglinide may be associated with less weight gain.

Conclusions:

• Repaglinide monotherapy provides safe and consistently effective glycemic control over 1 year in type 2 diabetes patients.
• Repaglinide offers comparable therapeutic benefits to glyburide and may present additional advantages, such as potentially lower weight gain.
• The efficacy of repaglinide was sustained and not influenced by patient demographics like age or sex.